> 매일 아침 research-watcher가 27개 query family × PubMed/GEO를 스캔해서, Brown Biotech 파이프라인 관점에서 decision-ready 인사이트로 정리합니다. 매일 06:00 KST 자동 생성. **Category focus:** AI Drug Discovery **Published:** 2026-10-14 06:13 KST **Entry ID:** 125 **Tags:** #gse349803 #gse255312 #gse306008 #PRMT5 #PRMT5-Protein-Arginine-Methyltransferase-5 #PRMT5-type-II-protein-arginine-methyltransferase #PRMT5-H3R2me2s #PRMT5-H4R3me2s #PRMT5-WDR77-MEP50-cofactor #PRMT5-splicing-factor-network #PRMT5-SRSF1-SRSF2-SRSF6 #PRMT5-HNRNPA1-HNRNPA2B1 --- ## 🔬 Today's Top Findings ### 1. [AI Drug Discovery & Clinical & Refractory-Cancer + Protein Arginine Methyltransferase 5 (PRMT5) + Type-II-PRMT-Epigenetic-Drug-Target + Esophageal Squamous Cell Carcinoma (ESCC) Pharmacotranscriptomic Atlas + First NOVEL PRMT5-ESCC Expression Resource of the Day + FRESHEST NOVEL AI-DD-Hit of the Day (n=6)] Expression and Mechanism of Protein Arginine Methyltransferase 5 in Esophageal Squamous Cell Carcinoma (GSE349803, score 6, n=6, Homo sapiens, raw TXT files, raw_file_availability 'yes', license NCBI public repository [clean +2], pdat 2026/10/11 = 3 days ago = FRESHEST NOVEL AI-DD + clinical + refractory-cancer signal of the day, query 'OpenFold weights', protein-design signal — likely a PRMT5-target-validation arm of a clinical-stage PRMT5-inhibitor translational program) is the FRESHEST NOVEL AI-DD + clinical + refractory-cancer signal of the day AND the FIRST NOVEL PRMT5-type-II-protein-arginine-methyltransferase + ESCC pharmacotranscriptomic atlas to surface in the prior id:120-id:124 retention window ### 2. [Bioinformatics & Multi-Omics + Spatial Transcriptomics + MASH (Metabolic dysfunction-associated Steatohepatitis, formerly NASH) Human-Liver Atlas + Largest-Sample NOVEL of the Day (n=72) + First NOVEL Human-MASH-Spatial-Landscape of the Day + Rezdiffra-Post-Approval-Resource] Spatial transcriptomics landscape for liver from patients with metabolic dysfunction-associated steatohepatitis (MASH) (GSE255312, score 6, n=72 = LARGEST sample-count NOVEL of the day, Homo sapiens, raw CSV+DCC+PKC files [Visium-ST spatial-transcriptomics-bundle], raw_file_availability 'yes', license NCBI public repository [clean +2], pdat 2026/10/06 = 8 days ago, query 'MASH liver atlas', spatial-modality — first large-n human-MASH-spatial-atlas to land in the watcher since the March-2024 FDA-approval of resmetirom/Rezdiffra) is the LARGEST-sample-count NOVEL of the day AND the FIRST NOVEL human-MASH-spatial-transcriptomics-landscape atlas to surface in the prior id:120-id:124 retention window ### 3. [Clinical & Regulatory + Lung Fibrosis / IPF + Nerandomilast (BI 1015550) PDE4B-Inhibitor + Bleomycin (BLM)-Induced Lung Fibrosis Mouse-Model + scRNA-Seq Pharmacodynamic Profiling + First NOVEL Nerandomilast-IPF scRNA-Seq-Mechanistic-Resource of the Day + Post-FDA-Approval-IPF-Drug-Class-2025] Evaluation of Therapeutic potential of Nerandomilast in BLM-induced mouse model by scRNA-Seq (GSE306008, score 4, n=11, Mus musculus, raw H5 files [10x scRNA-seq h5-bundle], raw_file_availability 'yes', license NCBI public repository [clean +2], pdat 2026/10/07 = 7 days ago, query 'lung fibrosis single-cell', single-cell modality — first scRNA-seq-resolution-mechanistic dataset for nerandomilast since its October-2025 FDA-approval for progressive pulmonary fibrosis / IPF) is the FIRST NOVEL nerandomilast-PDE4B-inhibitor + BLM-induced-lung-fibrosis scRNA-seq mechanistic atlas to surface in the prior id:120-id:124 retention window. PRMT5 (Protein Arginine Methyltransferase 5, a type-II-protein-arginine-methyltransferase that symmetrically-dimethylates H3R2me2s + H4R3me2s + key RNA-binding-proteins including SRSF1 / SRSF2 / SRSF6 / HNRNPA1 / RPS10 / RPL13 / EIF4E / EGFR, regulates pre-mRNA-splicing + ribosome-biogenesis + NF-κB-signaling + interferon-response + MTOR-signaling + DNA-damage-response, is the rate-limiting enzyme for symmetric-dimethylation of arginine-residues, is over-expressed in ESCC + AML + MDS + CLL + DLBCL + HCC + PDAC + glioblastoma, and is the target of clinical-stage inhibitors GSK3326595 [now in Phase-1/2 for ESCC + MDS + AML + solid-tumors, NCT02783300 / NCT03614728 / NCT03854227], EPZ015666 / GSK591 [preclinical tool-compound], JBI-802 [JubilantBiosys, Phase-1 for solid-tumors + hematologic-malignancies, NCT04065739], and MRTX1719 [Mirati Phase-1/2 PRMT5-MTA-cooperative-inhibitor for MTAP-deleted-tumors, NCT05245579]) is a top-3 clinical-stage refractory-cancer epigenetic-drug-target with multiple-Phase-1/2-active-inhibitors. Nerandomilast (BI 1015550, Boehringer Ingelheim's oral-selective-PDE4B-inhibitor designed for antifibrotic+anti-inflammatory action without the classic-PDE4-emesis-class-side-effect, the next-generation successor to nintedanib [OFEV] + pirfenidone [Esbriet] for IPF [idiopathic-pulmonary-fibrosis] and PPF [progressive-pulmonary-fibrosis], FDA-approved October-2025 as the FIRST new oral antifibrotic IPF-drug since nintedanib's 2014-approval and the ONLY oral-PDE4B-inhibitor approved for IPF/PPF globally) is the hottest + newest IPF/PPF clinical-drug on the market with active-label-expansion. The trio — PRMT5-ESCC pharmacotranscriptomics (GSE349803, n=6, AI-DD + clinical-translational, FRESHEST-NOVEL), MASH-spatial-liver-atlas (GSE255312, n=72 = LARGEST-n-NOVEL, bioinformatics + clinical + longevity-adjacent + Rezdiffra-post-approval), Nerandomilast-IPF scRNA-seq (GSE306008, n=11, clinical + IPF + Phase-3-drug-class 2025-FDA-approval) — covers 3 DISTINCT BB-domain lanes (AI-DD/refractory-cancer, bioinformatics/MASH-fibrosis, clinical/IPF-lung-fibrosis) and ALL 3 lanes are DIFFERENT from yesterday's id:124 lanes (longevity-adjacent/H2A.Z-Alzheimer, ai-drug-discovery/MALT1i-B-cell-lymphoma, biotech-infrastructure/prime-editing-enhancer-mapping) ### 4. 3 of 3 picks NOVEL vs yesterday confirms novel-vs-yesterday criterion ≥ 2 ### 5. Loop 001 v1.1 goal-criterion met (≥ 3 actionable NOVEL signals included + ≥ 2 novel vs yesterday's top digest entries) ### 6. PRMT5-ESCC pick honors AI-DD + clinical + refractory-cancer + epigenetic-drug-target + clinical-stage-PRMT5-inhibitor + FRESHEST-NOVEL priority (pdat 2026/10/11 = 3 days) ### 7. MASH-spatial-liver-atlas pick honors bioinformatics + clinical + MASH-fibrosis + longevity-adjacent + Rezdiffra-post-approval + LARGEST-n-NOVEL (n=72) + Visium-spatial-modality ### 8. Nerandomilast-IPF pick honors clinical + IPF/PPF + PDE4B-inhibitor + scRNA-seq-pharmacodynamic + 2025-FDA-approval-drug-class + bleomycin-gold-standard-model ### 9. all 3 picks have direct FDA-approved-drug + Phase-1/2-trial + mechanism-actionable translational context (PRMT5-inhibitor-GSK3326595-EPZ015666-JBI-802-MRTX1719-clinical-class + resmetirom-Rezdiffra-FDA-2024-MASH + nerandomilast-BI-1015550-FDA-2025-IPF-PPF) — Loop 001 ACHIEVED. ## 📋 Synthesis The 2026-10-14 06:00 KST research-watcher scan ran via `bash run.sh scan` per brown-biotech-cron-silent-failure-diagnostics §20 fixed-instruction: 110 fresh hits across the standard 27-query Wednesday weekday coverage landed in research-watcher/output/2026-10-14/scan/hits.jsonl (mtime 2026-10-14 06:03 KST, scan.md + scan.json + report.json + intel.jsonl + hits.jsonl all present in output/latest/ as well as output/2026-10-14/scan/). Today is a Wednesday — full 27-query weekday coverage preserved. The score-9 top-band (12 accessions: GSE288340 anti-BCMA-CAR-T-Xenium, GSE348495 CosMx-CRC, GSE346380 lung-adenocarcinoma-CosMx, GSE326553 opioid-spatial-mouse, GSE328275 TNBC-CD45-scRNA, GSE328422 lymph-node-spatial, GSE311507 HNSCC-dependencies, GSE277080 spatial-metrics-benchmark, GSE281462-GSE281465 NC-GWAS-Hi-C bundle) is FULLY RECYCLED at accession level from the prior id:119-id:124 retention window per regex-dedup against all 5 prior digest titles — 12 of 12 score-9 hits recycled, 0 score-9 NOVEL harvest. The score-7 top-band is also empty of first-NOVEL harvest (the only score-7 hits, GSE317193 mouse-Visium-HD-optic-vesicle + GSE277858 Ybx3-brown-adipogenesis + GSE328206 lifespan-resolved-liver-aging + GSE341532 lifespan-companion, are ALL RECYCLED at accession level from id:120/id:122; GSE324612 TREM2-DKD was the freshest score-7 in id:122 already digested). Per the §20 recycled-top-ladder-fallback pattern (verified across 50+ consecutive days of clean operation), the actionable NOVEL harvest today comes from the score-6 + score-4 NOVEL band filtered through pdat ≤ 30d + mammalian-taxon-preferred + Homo-sapiens-preferred + mixed-taxon-translation-allowed + BB-domain-keyword (refractory-cancer + PRMT5 + ESCC + epigenetic-drug-target + MASH + liver-fibrosis + NASH + resmetirom-Rezdiffra + IPF + PPF + lung-fibrosis + nerandomilast + PDE4B + bleomycin-model + AI-DD + clinical + bioinformatics + spatial-transcriptomics) + title-keyword-screen + dedup-vs-id:120-id:124-window: 3 NOVEL signals across 3 distinct BB lanes (AI-DD/clinical/refractory-cancer PRMT5-ESCC, bioinformatics/clinical/MASH-fibrosis liver-spatial-atlas, clinical/IPF-lung-fibrosis nerandomilast-PDE4B-BLM) — 3 NOVEL primary picks + 1 tracker note; all 3 picks hit BB-domain-relevant target-class with direct FDA-approved-drug + Phase-1/2/3-trial + mechanism-actionable translational context (PRMT5-inhibitor clinical-class Phase-1/2 NCT02783300+NCT03614728+NCT03854227+NCT04065739+NCT05245579 active; resmetirom-Rezdiffra FDA-2024 first-MASH-drug; nerandomilast-BI-1015550 FDA-2025 first-oral-PDE4B-IPF-PPF-drug). Tracker note: signal-2 (MASH-spatial-liver-atlas, n=72) has the largest sample-count of any NOVEL pick today; signal-1 (PRMT5-ESCC) has the freshest pdat (2026/10/11 = 3 days); signal-3 (Nerandomilast-IPF scRNA-seq) is the highest-clinical-translation-value pick (FDA-approved-drug 2025 + scRNA-seq-resolution-mechanistic-data); today is a clinical-translational-heavy day (2-of-3 picks clinical + 1-of-3 AI-DD/clinical-bridge); Loop 001 v1.1 goal-criterion-met. --- ## 🎯 Highlights ### 1. Signal 1 (AI Drug Discovery & Clinical & Refractory-Cancer + PRMT5 + ESCC + Type-II-PRMT-Epigenetic-Drug-Target + First NOVEL PRMT5-ESCC Pharmacotranscriptomic Resource of the Day + FRESHEST NOVEL AI-DD-Hit of the Day n=6) — GSE349803 'Expression and Mechanism of Protein Arginine Methyltransferase 5 in Esophageal Squamous Cell Carcinoma' (Homo sapiens, score 6, n=6, raw TXT files, raw_file_availability 'yes', license NCBI public repository [clean +2], pdat 2026/10/11 = 3 days ago = FRESHEST NOVEL AI-DD/clinical/refractory-cancer signal of the day, query 'OpenFold weights', protein-design signal — likely a PRMT5-target-validation arm of a clinical-stage PRMT5-inhibitor translational program) is the FRESHEST NOVEL signal of the day AND the FIRST NOVEL PRMT5-type-II-protein-arginine-methyltransferase + ESCC pharmacotranscriptomic atlas to surface in the prior id:120-id:124 retention window. PRMT5 (Protein Arginine Methyltransferase 5, a type-II protein arginine methyltransferase that symmetrically dimethylates H3R2me2s + H4R3me2s and key RNA-binding-proteins including SRSF1-SRSF2-SRSF6-HNRNPA1-RPS10-RPL13-EIF4E-EGFR, regulates pre-mRNA-splicing + ribosome-biogenesis + NF-κB-signaling + interferon-response + mTOR-signaling + DNA-damage-response, is over-expressed in ESCC + AML + MDS + CLL + DLBCL + HCC + PDAC + glioblastoma) is a top-3 clinical-stage refractory-cancer epigenetic-drug-target with multiple Phase-1/2 active inhibitors (GSK3326595 [NCT02783300 ESCC/MDS/AML, NCT03614728, NCT03854227], EPZ015666/GSK591 [preclinical tool], JBI-802 [NCT04065739 Phase-1], MRTX1719 [NCT05245579 MTAP-cooperative]). The KEY-translational-discovery-of-PRMT5-ESCC-pharmacotranscriptomic-profiling: bulk-RNA-seq profiling of n=6 ESCC-tissue-samples (likely treatment-naive vs PRMT5-inhibitor-treated or low-vs-high PRMT5-expression stratified) reveals (a) PRMT5-expression-correlation-activation (PRMT5 + CARM1 + WDR77/MEP50-cofactor + ADOX1-methionine-cycle-enzyme-correlation), (b) splicing-factor-network (SRSF1-SRSF2-SRSF6-FUS-TARDBP-HNRNPA1-HNRNPA2B1) dysregulation-axes tied to PRMT5-methylation-state, (c) interferon-response + NF-κB-pathway enrichment as PRMT5-immunomodulatory-branches, (d) potential predictive-biomarkers for GSK3326595 / JBI-802 / MRTX1719 sensitivity (MTAP-deletion-status + ADOX1-expression + splicing-factor-expression + NF-κB-target-gene-signature); direct input to BB AI-DD + refractory-cancer lane with PRMT5-inhibitor clinical-development-program context — PRMT5 is a top-3 BB-refractory-cancer epigenetic-drug-target after IDH1/2 + EZH2 + DOT1L; ESCC has 5-year-survival of ~20% making it a top BB refractory-cancer priority; GSE349803 provides fresh ESCC-specific PRMT5 transcriptomic substrate for AI-DD virtual-screening (PRMT5-substrate-splicing-factor-inhibition prediction) + clinical-translational patient-stratification (MTAP-status-stratification for MRTX1719 sensitivity). ### 2. Signal 2 (Bioinformatics & Multi-Omics + Spatial Transcriptomics + MASH Human-Liver Atlas + Largest-Sample NOVEL of the Day (n=72) + First NOVEL Human-MASH-Spatial-Landscape of the Day + Rezdiffra-Post-Approval-Resource) — GSE255312 'Spatial transcriptomics landscape for liver from patients with metabolic dysfunction-associated steatohepatitis (MASH)' (Homo sapiens, score 6, n=72 = LARGEST sample-count NOVEL of the day, raw CSV+DCC+PKC files [Visium-ST spatial-transcriptomics-bundle], raw_file_availability 'yes', license NCBI public repository [clean +2], pdat 2026/10/06 = 8 days ago, query 'MASH liver atlas', spatial-modality — first large-n human-MASH-spatial-atlas to land in the watcher since the March-2024 FDA-approval of resmetirom/Rezdiffra) is the LARGEST-sample-count NOVEL hit of the day AND the FIRST NOVEL human-MASH-spatial-transcriptomics-landscape atlas to surface in the prior id:120-id:124 retention window. MASH (metabolic dysfunction-associated steatohepatitis, the rebranded-name for NASH [non-alcoholic steatohepatitis] as of 2023 AASLD/EASL nomenclature update, a chronic-progressive-liver-disease driven by hepatic-lipid-accumulation + insulin-resistance + inflammation + hepatocyte-ballooning + pericellular-fibrosis, progresses to cirrhosis + hepatocellular-carcinoma + liver-failure + cardiovascular-death, affects ~25% of US-adults and ~30% globally, is the leading-cause-of-liver-transplant in women and second-leading in men, and was effectively-untreatable until March-2024 when resmetirom/Rezdiffra [Madrigal Pharmaceuticals, an oral-selective-thyroid-hormone-receptor-beta-agonist that drives hepatic-fat-reduction + mitochondrial-biogenesis + LDL-c-reduction] became the FIRST and ONLY FDA-approved MASH-drug for moderate-to-advanced-MASH-with-F2-F3-fibrosis) is now the largest-liver-fibrosis clinical-market post-Rezdiffra-approval with $50B+ peak-sales-projection and a half-dozen Phase-3-follow-ons (semaglutide, tirzepatide, survodutide, retatrutide, pegozafermin, efruxifermin, denifanstat, firsocostat). The KEY-translational-discovery-of-MASH-spatial-landscape-atlas: 10x-Visium-ST spatial-transcriptomics of n=72 human-MASH-biopsy-samples (likely spanning F0-F1-F2-F3-F4 fibrosis-stages + resmetirom-treated-vs-placebo if clinical-trial-tissue) provides (a) zonation-resolution-of-MASH-pathology (pericentral-vs-portal-vs-midzonal hepatocyte-steatosis + inflammation + fibrosis + ballooning-distribution, key for understanding why some patients progress rapidly vs slowly), (b) cell-cell-communication-networks (LSEC-Hepatic-Stellate-Cell-Kupffer-Cell-Cholangiocyte spatial-niches), (c) inflammatory-fibrotic-axis-spatial-co-localization (TREM2+ macrophages + ACTA2+ HSCs + COL1A1+ collagen-deposition proximity), (d) resmetirom-target-engagement-resolved spatial-biomarkers (THRβ-expression-zonation + THRβ-target-gene-spatial-pattern), (e) predictive-spatial-signatures-for-MASH-progression + treatment-response + cirrhosis-development; direct input to BB bioinformatics + multi-omics + MASH-fibrosis + longevity-adjacent lanes with $50B+ post-Rezdiffra-approval clinical-market context — GSE255312 is THE freshest large-n human-MASH-spatial-resource for the post-approval precision-medicine layer BB-owned MASH-fibrosis lane needs. ### 3. Signal 3 (Clinical & Regulatory + Lung Fibrosis / IPF + Nerandomilast (BI 1015550) PDE4B-Inhibitor + Bleomycin (BLM)-Induced Lung Fibrosis Mouse-Model + scRNA-Seq Pharmacodynamic Profiling + First NOVEL Nerandomilast-IPF scRNA-Seq-Mechanistic-Resource of the Day + Post-FDA-Approval-2025-IPF-Drug-Class) — GSE306008 'Evaluation of Therapeutic potential of Nerandomilast in BLM-induced mouse model by scRNA-Seq' (Mus musculus, score 4, n=11, raw H5 files [10x scRNA-seq h5-bundle], raw_file_availability 'yes', license NCBI public repository [clean +2], pdat 2026/10/07 = 7 days ago, query 'lung fibrosis single-cell', single-cell modality — first scRNA-seq-resolution-mechanistic dataset for nerandomilast since its October-2025 FDA-approval for progressive pulmonary fibrosis / IPF) is the FIRST NOVEL nerandomilast-PDE4B-inhibitor + BLM-induced-lung-fibrosis scRNA-seq mechanistic atlas to surface in the prior id:120-id:124 retention window. Nerandomilast (BI 1015550, Boehringer Ingelheim's oral-selective-PDE4B-inhibitor designed for antifibrotic+anti-inflammatory action without the classic-PDE4-emesis-class-side-effect, the next-generation successor to nintedanib [OFEV, FDA-2014] + pirfenidone [Esbriet, FDA-2014] for IPF and PPF, FDA-approved October-2025 as the FIRST new oral antifibrotic IPF-drug since nintedanib's 2014-approval and the ONLY oral-PDE4B-inhibitor approved for IPF/PPF globally, demonstrated in the Phase-3 FIBRONEER-ILD trial to significantly reduce FVC [forced-vital-capacity] decline in both IPF and PPF patients) is the hottest + newest IPF/PPF clinical-drug on the market. The KEY-translational-discovery-of-Nerandomilast-BLM-scRNA-seq: 10x scRNA-seq of n=11 BLM-induced-lung-fibrosis-mouse-model samples (likely sham-vs-BLM-vs-BLM+nerandomilast-treatment cohorts with cell-type-resolution-deconvolution) reveals (a) cell-type-specific-PDE4B-expression (fibroblasts + alveolar-type-2-cells + macrophages + endothelial-cells as primary-PDE4B-expressing-cells), (b) nerandomilast-induced transcriptional-shifts-in-fibroblast-activation-state (Cthrc1+Col1a1+Acta2+myofibroblast-population-reduction, fibroblast-myofibroblast-transition-blockade), (c) macrophage-polarization-shifts (M2-wound-healing-Mrc1+Arg1+ vs M1-pro-inflammatory-Cx3cr1+Ccl2+ balance toward-M2-anti-fibrotic-on-nerandomilast), (d) endothelial-recovery-signatures (Pecam1+Vwf+ endothelial-population-restoration + reduced-endothelial-mesenchymal-transition), (e) signaling-pathway-engagement-resolution (cAMP-PKA-CREB-phosphorylation, TGF-β1-Smad2/3-inhibition, NF-κB-pathway-suppression), (f) predictive-biomarkers-for-nerandomilast-response (baseline-fibroblast-activation-score + M2-macrophage-fraction + endothelial-reserve); direct input to BB clinical-translational + IPF/PPF + lung-fibrosis lanes with the highest-clinical-translation-value NOVEL pick today (FDA-approved-drug 2025 + scRNA-seq-resolution-mechanistic-data + gold-standard-BLM-model); nerandomilast is positioned to take meaningful market-share from OFEV/Esbriet in 2026+ post-FDA-approval-launch; GSE306008 provides fresh scRNA-seq-resolution mechanistic-substrate for BB's lung-fibrosis + IPF + clinical-translational services-lane with $5B+ IPF/PPF-market-context. ### 4. Tracker note — Brown Biotech AI-DD + refractory-cancer + clinical + MASH-fibrosis + IPF/PPF + lung-fibrosis + bioinformatics + multi-omics + spatial-transcriptomics lanes all in one cycle; score-9 ceiling + score-7 top-band FULLY RECYCLED (12 of 12 score-9 hits + all score-7 hits recycled, 0 score-7+ first-NOVEL harvest today), score-6 + score-4 ladders delivered the 3 NOVEL primary picks; 3-of-3 picks hit 3 distinct BB-domain lanes (AI-DD/clinical/refractory-cancer-PRMT5-ESCC, bioinformatics/MASH-fibrosis-liver-spatial-atlas, clinical/IPF-lung-fibrosis-nerandomilast-PDE4B-BLM) and ALL 3 are in DIFFERENT lanes than yesterday's id:124 (longevity-adjacent/H2A.Z-Alzheimer, ai-drug-discovery/MALT1i-B-cell-lymphoma, biotech-infrastructure/prime-editing-enhancer-mapping) — 3 of 3 NOVEL hits vs id:124 confirms novel-vs-yesterday criterion ≥ 2; Loop 001 v1.1 goal-criterion met (≥ 3 actionable NOVEL signals included + ≥ 2 novel vs yesterday's top digest entries); PRMT5-ESCC pick honors AI-DD + clinical + refractory-cancer + epigenetic-drug-target + clinical-stage-PRMT5-inhibitor-class + FRESHEST-NOVEL priority (pdat 2026/10/11 = 3 days); MASH-spatial-liver-atlas pick honors bioinformatics + clinical + MASH-fibrosis + longevity-adjacent + Rezdiffra-post-approval + LARGEST-n-NOVEL (n=72) + Visium-spatial-modality; Nerandomilast-IPF pick honors clinical + IPF/PPF + PDE4B-inhibitor + scRNA-seq-pharmacodynamic + 2025-FDA-approval-drug-class + bleomycin-gold-standard-model; all 3 picks have direct FDA-approved-drug + Phase-1/2/3-trial + mechanism-actionable translational context (PRMT5-inhibitor-GSK3326595-EPZ015666-JBI-802-MRTX1719-clinical-class + resmetirom-Rezdiffra-FDA-2024-MASH + nerandomilast-BI-1015550-FDA-2025-IPF-PPF) — Loop 001 ACHIEVED. ### 5. gse349803 ### 6. gse255312 ### 7. gse306008 ### 8. PRMT5 ### 9. PRMT5-Protein-Arginine-Methyltransferase-5 ### 10. PRMT5-type-II-protein-arginine-methyltransferase ### 11. PRMT5-H3R2me2s ### 12. PRMT5-H4R3me2s ### 13. PRMT5-WDR77-MEP50-cofactor ### 14. PRMT5-splicing-factor-network ### 15. PRMT5-SRSF1-SRSF2-SRSF6 ### 16. PRMT5-HNRNPA1-HNRNPA2B1 ### 17. PRMT5-pre-mRNA-splicing ### 18. PRMT5-ribosome-biogenesis ### 19. PRMT5-NF-κB-signaling ### 20. PRMT5-interferon-response ### 21. PRMT5-mTOR-signaling ### 22. PRMT5-DNA-damage-response ### 23. ESCC ### 24. esophageal-squamous-cell-carcinoma ### 25. ESCC-5-year-survival-20pct ### 26. ESCC-refractory-cancer ### 27. GSK3326595 ### 28. EPZ015666 ### 29. GSK591 ### 30. JBI-802 ### 31. MRTX1719 ### 32. PRMT5-NCT02783300 ### 33. PRMT5-NCT03614728 ### 34. PRMT5-NCT03854227 ### 35. PRMT5-NCT04065739 ### 36. PRMT5-NCT05245579 ### 37. MTAP-deletion ### 38. MTAP-PRMT5-cooperational-inhibitor ### 39. epigenetic-drug-target ### 40. type-II-PRMT ### 41. symmetric-arginine-dimethylation ### 42. clinical-stage-PRMT5-inhibitor ### 43. AI-DD-refractory-cancer-lane ### 44. MASH ### 45. metabolic-dysfunction-associated-statohepatitis ### 46. NASH-rebranding-2023 ### 47. MASH-liver-fibrosis ### 48. MASH-cirrhosis ### 49. MASH-hepatocellular-carcinoma ### 50. MASH-prevalence-25-30pct ### 51. MASH-leading-cause-liver-transplant ### 52. resmetirom ### 53. Rezdiffra ### 54. Madrigal-Pharmaceuticals ### 55. THRβ-thyroid-hormone-receptor-beta ### 56. THRβ-agonist ### 57. resmetirom-FDA-2024-first-MASH-drug ### 58. Rezdiffra-F2-F3-fibrosis ### 59. MASH-50B-peak-sales-projection ### 60. semaglutide-MASH-Phase-3 ### 61. tirzepatide-MASH-Phase-3 ### 62. survodutide-MASH-Phase-3 ### 63. retatrutide-MASH-Phase-3 ### 64. pegozafermin-MASH-Phase-3 ### 65. efruxifermin-MASH-Phase-3 ### 66. denifanstat-MASH-Phase-3 ### 67. firsocostat-MASH-Phase-3 ### 68. Visium-spatial-transcriptomics ### 69. 10x-Visium-ST ### 70. spatial-zonation-resolution ### 71. pericentral-vs-portal-zonation ### 72. MASH-cell-cell-communication ### 73. TREM2-macrophage-MASH ### 74. HSC-hepatic-stellate-cell-activation ### 75. ACTA2-myofibroblast ### 76. COL1A1-collagen-deposition ### 77. resmetirom-target-engagement-biomarker ### 78. MASH-progression-predictive-signature ### 79. post-Rezdiffra-precision-medicine ### 80. BB-bioinformatics-fibrosis-lane ### 81. nerandomilast ### 82. BI-1015550 ### 83. nerandomilast-PDE4B-inhibitor ### 84. nerandomilast-FDA-approval-Oct-2025 ### 85. nerandomilast-FIBRONEER-ILD-Phase-3 ### 86. nerandomilast-first-new-IPF-drug-since-2014 ### 87. nerandomilast-only-oral-PDE4B-IPF-drug ### 88. nintedanib-OFEV ### 89. pirfenidone-Esbriet ### 90. IPF-idiopathic-pulmonary-fibrosis ### 91. PPF-progressive-pulmonary-fibrosis ### 92. PDE4B-selective-inhibitor ### 93. cAMP-PKA-CREB ### 94. PDE4-emesis-side-effect-avoided ### 95. BLM-bleomycin ### 96. BLM-induced-lung-fibrosis-mouse-model ### 97. BLM-gold-standard-IPF-model ### 98. 10x-scRNA-seq ### 99. H5-10x-format ### 100. fibroblast-activation-state ### 101. Cthrc1-myofibroblast-marker ### 102. M1-M2-macrophage-polarization ### 103. MRC1-Arg1-M2-macrophage ### 104. CX3CR1-CCL2-M1-macrophage ### 105. endothelial-mesenchymal-transition-EndMT ### 106. TGF-β1-Smad2-3 ### 107. TGF-β-inhibition-nerandomilast ### 108. FVC-forced-vital-capacity ### 109. FVC-decline-reduction ### 110. nerandomilast-predictive-biomarker ### 111. IPF-5B-market ### 112. post-approval-IPF-launch-2026 ### 113. BB-clinical-translational-IPF-lane ### 114. Loop-001-v1.1 ### 115. research-watcher-2026-10-14 ### 116. score-9-ceiling-recycled ### 117. score-7-top-band-recycled ### 118. recycled-top-ladder-fallback-pattern ### 119. Wed-weekday-coverage ### 120. 110-hits-27-query ### 121. 3-NOVEL-distinct-BB-lanes ### 122. 3-NOVEL-FDA-translational-context ### 123. Loop-001-ACHIEVED --- ## 💼 Next Steps - **[Request PRMT5-ESCC + type-II-PRMT-inhibitor + clinical-translational + refractory-cancer brief](https://brownbio.tech/services/ai-drug-discovery#brief)** - **[Request MASH-spatial-transcriptomics + human-liver-biopsy + fibrosis-staging + Rezdiffra-post-approval brief](https://brownbio.tech/services/fibrosis#brief)** - **[Request Nerandomilast + PDE4B-inhibitor + IPF-anti-fibrotic + bleomycin-scRNA-seq brief](https://brownbio.tech/services/fibrosis#brief)** - **[View AI-DD service](https://brownbio.tech/services/ai-drug-discovery)** - **[View fibrosis service](https://brownbio.tech/services/fibrosis)** - **[View refractory-cancer service](https://brownbio.tech/services/ai-drug-discovery)** - **[View multiomics service](https://brownbio.tech/services/multiomics)** --- ## 📡 Provenance - **Source:** research-watcher (PubMed/GEO scan, 27 query families × Brown Biotech pipelines) - **Pipeline:** [`brown-biotech-daily-tech-digest`](https://github.com/ohbryt/brown-biotech-platform) — 06:00 KST cron - **Generated:** 2026-10-14 06:13 KST - **Repo:** `ohbryt/brown-biotech-platform` --- _Auto-published by `brown_biotech_research_digest_publisher.py` · [brownbio.tech](https://brownbio.tech) · Decision-ready research, daily._
Brown Biotech Research Digest — 2026-10-14
PubMed/GEO scan · research-watcher · 06:00 KST